title: Peripheral PDLIM5 expression in bipolar disorder and the effect of olanzapine administration.
abstract: BACKGROUND
  One of the genes suggested to play an important role in the pathophysiology of bipolar disorder (BPD) is PDLIM5, which encodes LIM domain protein. Our main objective was to examine the effect of olanzapine treatment on PDLIM5 mRNA expression in the peripheral blood leukocytes of BPD patients.
  
  
  METHODS
  We measured the expression of PDLIM5 mRNA from 16 patients with BPD Type I after 0, 4, and 8 weeks of treatment with olanzapine using quantitative real-time PCR. The Young Mania Rating Scale was used to evaluate the severity of manic symptoms in BPD patients. We also compared PDLIM5 mRNA expression in treatment-naïve BPD patients with that in healthy control subjects.
  
  
  RESULTS
  No significant difference was found in PDLIM5 mRNA expression between patients before olanzapine treatment and following 4 and 8 weeks of treatment (p>0.05). Although we observed a significant reduction in the severity of manic symptoms in all BPD patients (p<0.05), the effectiveness of the medication did not significantly correlate with the expression of PDLIM5 mRNA (p>0.05). Interestingly, PDLIM5 mRNA expression differed significantly between treatment-naïve BPD patients and healthy control subjects (p=0.002).
  
  
  CONCLUSIONS
  PDLIM5 mRNA expression did not appear to be a reflection of the efficacy of olanzapine in reducing the manic symptoms of BPD. The significant difference in expression of PDLIM5 mRNA in the peripheral blood leukocytes of treatment-naïve BPD patients versus that of healthy control subjects, however, suggests that it may be a good biological marker for BPD.
authors.affiliation: The Pharmacogenomics Laboratory, Department of Pharmacology, University of Malaya, 50603 Kuala Lumpur, Malaysia. aizat03@gmail.com
authors.forename: Mohd Aizat
authors.initials: MA
authors.lastname: Zain
authors.forename: Suffee Nusrat
authors.initials: SN
authors.lastname: Jahan
authors.forename: Gavin P
authors.initials: GP
authors.lastname: Reynolds
authors.forename: Nor Zuraida
authors.initials: NZ
authors.lastname: Zainal
authors.forename: Sharmilla
authors.initials: S
authors.lastname: Kanagasundram
authors.forename: Zahurin
authors.initials: Z
authors.lastname: Mohamed
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000235:genetics*; D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000097:blood / Q000188:drug therapy* / Q000235:genetics*; D016022:Case-Control Studies; D005260:Female; D015870:Gene Expression / Q000187:drug effects; D005819:Genetic Markers; D006801:Humans; D060588:LIM Domain Proteins / Q000235:genetics*; D007962:Leukocytes / Q000187:drug effects / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D020641:Polymorphism, Single Nucleotide; D012333:RNA, Messenger / Q000097:blood / Q000235:genetics
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D014150:Antipsychotic Agents; D005819:Genetic Markers; D060588:LIM Domain Proteins; C512485:PDLIM5 protein, human; D012333:RNA, Messenger; D001569:Benzodiazepines; D000077152:Olanzapine